Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Heron Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Heron Therapeutics' CEO'su Craig Collard, Apr2023 tarihinde atandı, in görev süresi 1.5 yıldır. şirketin hisselerinin 0.17% doğrudan sahiptir ve bu hisselerin değeri $ 498.61K dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.3 yıl ve 3.1 yıldır.

Anahtar bilgiler

Craig Collard

İcra Kurulu Başkanı

US$5.5k

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	1.5yrs
CEO sahipliği	0.2%
Yönetim ortalama görev süresi	1.3yrs
Yönetim Kurulu ortalama görev süresi	3.1yrs

Son yönetim güncellemeleri

Recent updates

Investors Don't See Light At End Of Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Tunnel And Push Stock Down 32%

Aug 08

Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Share Price Boosted 31% But Its Business Prospects Need A Lift Too

May 30

Heron Therapeutics: Zynrelef Potentially Eases Shareholder Pain

Apr 16

Here's What Analysts Are Forecasting For Heron Therapeutics, Inc. (NASDAQ:HRTX) After Its Full-Year Results

Mar 15

Heron Therapeutics, Inc. (NASDAQ:HRTX) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Feb 15

Heron Therapeutics, Inc. (NASDAQ:HRTX) Held Back By Insufficient Growth Even After Shares Climb 27%

Dec 22

Need To Know: Analysts Just Made A Substantial Cut To Their Heron Therapeutics, Inc. (NASDAQ:HRTX) Estimates

Aug 11

Shareholders May Be A Bit More Conservative With Heron Therapeutics, Inc.'s (NASDAQ:HRTX) CEO Compensation For Now

Jun 11

Heron Therapeutics files for 12.4M common stock offering from shareholder

May 28

CEO

Craig Collard (58 yo)

1.5yrs

Görev süresi

US$5,486

Tazminat

Mr. Craig Alexander Collard serves as Chief Executive Officer at Heron Therapeutics, Inc. since April 3, 2023 and its Director since February 2023. He had been Chief Executive Officer of Veloxis Pharmaceut...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Craig Collard	CEO & Director	1.5yrs	US$5.49k	0.17% $ 531.2k
Ira Duarte	Executive VP & CFO	1.3yrs	US$1.76m	0.069% $ 220.7k
William Forbes	Executive VP & Chief Development Officer	1.3yrs	US$1.71m	0.065% $ 210.4k
Ryan Craig	Vice President of Marketing	1.2yrs	Veri yok	Veri yok
Sean Ristine	Senior Vice President of Human Resources	9.1yrs	Veri yok	Veri yok
Robert Sullivan	Senior Vice President of Oncology Care Franchise & Commercial Operations	1.8yrs	Veri yok	Veri yok
Brett Fleshman	Chief Business Officer	less than a year	Veri yok	Veri yok
Jeff Cohn	Executive Director	no data	Veri yok	Veri yok

1.3yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim: HRTX 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.3 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Craig Collard	CEO & Director	1.7yrs	US$5.49k	0.17% $ 531.2k
Craig Johnson	Independent Director	10.8yrs	US$11.02m	0.034% $ 110.0k
Christian Waage	Independent Director	8.3yrs	US$70.51k	0.034% $ 110.7k
Susan Rodriguez	Independent Director	3.1yrs	US$65.63k	0.035% $ 112.2k
Adam Morgan	Independent Chairman	1.7yrs	US$545.53k	0.0062% $ 20.1k
Sharmila Dissanaike	Independent Director	3.1yrs	US$55.00k	0.035% $ 112.2k

3.1yrs

Ortalama Görev Süresi

57.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: HRTX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.1 yıldır).

Heron Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Heron Therapeutics, Inc. Appoints Brett Fleshman as Chief Business Officer

Heron Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Kevin Kotler Resigns as A Member of the Board of Directors of Heron Therapeutics, Inc., Effective December 31, 2023

CEO & Director recently bought US$138k worth of stock

Heron Therapeutics, Inc. Announces Resignation of David Szekeres as Executive Vice President, Chief Operating Officer of the Company

Heron Therapeutics Announces Appointment of Ira Duarte as Chief Financial Officer

Recent updates

Heron Therapeutics, Inc. Appoints Brett Fleshman as Chief Business Officer

Consensus EPS estimates fall by 22%

Investors Don't See Light At End Of Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Tunnel And Push Stock Down 32%

Forecast breakeven date pushed back to 2026

Second quarter 2024 earnings: EPS misses analyst expectations

Heron Therapeutics, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Heron Therapeutics, Inc. Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System

Heron Therapeutics, Inc. Announces Acceptance of the Prior Approval Supplement Application for Zynrelef® Vial Access Needle

Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Share Price Boosted 31% But Its Business Prospects Need A Lift Too

Heron Therapeutics, Inc. Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN")

Consensus estimates of losses per share improve by 58%

Forecast breakeven date moved forward to 2025

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Heron Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Heron Therapeutics, Inc. to Report Q1, 2024 Results on May 07, 2024

Heron Therapeutics: Zynrelef Potentially Eases Shareholder Pain

Consensus estimates of losses per share improve by 51%

Here's What Analysts Are Forecasting For Heron Therapeutics, Inc. (NASDAQ:HRTX) After Its Full-Year Results

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Heron Therapeutics, Inc. Re-Affirms Earnings Guidance for the Full Year 2024

Heron Therapeutics, Inc. to Report Q4, 2023 Results on Mar 12, 2024

Price target decreased by 8.7% to US$6.67

Heron Therapeutics, Inc. (NASDAQ:HRTX) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Heron Therapeutics, Inc. Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures

Forecast to breakeven in 2026

Kevin Kotler Resigns as A Member of the Board of Directors of Heron Therapeutics, Inc., Effective December 31, 2023

Heron Therapeutics, Inc. (NASDAQ:HRTX) Held Back By Insufficient Growth Even After Shares Climb 27%

Consensus EPS estimates upgraded to US$0.90 loss

CEO & Director recently bought US$138k worth of stock

Price target decreased by 13% to US$6.50

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Heron Therapeutics, Inc. Provides Financial Guidance for the Year 2023 and 2024

Heron Therapeutics, Inc. to Report Q3, 2023 Results on Nov 14, 2023

New minor risk - Market cap size

Consensus EPS estimates fall by 30%

Second quarter 2023 earnings: EPS misses analyst expectations

Heron Therapeutics, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Heron Therapeutics, Inc. Announces Resignation of David Szekeres as Executive Vice President, Chief Operating Officer of the Company

Heron Therapeutics Announces Appointment of Ira Duarte as Chief Financial Officer

Heron Therapeutics Announces Appointment of William Forbes, Pharm.D. as Executive Vice President and Chief Development Officer

Heron Therapeutics, Inc. Announces Management Changes

Consensus EPS estimates fall by 17%

First quarter 2023 earnings: EPS misses analyst expectations

Heron Therapeutics, Inc. to Report Q1, 2023 Results on May 11, 2023

No longer forecast to breakeven

Full year 2022 earnings: EPS and revenues exceed analyst expectations

High number of new directors

Rubric Capital Management Engages with Heron Therapeutics

Forecast to breakeven in 2025

Heron Therapeutics, Inc. Provides Sales Guidance for the Full Year 2023

Forecast to breakeven in 2025

Heron Therapeutics, Inc. Announces the Submission of Supplemental New Drug Application for ZYNRELEF

Price target decreased to US$10.08

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Heron Therapeutics, Inc. Provides Sales Guidance for the Year 2022

Heron Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Heron Therapeutics, Inc. Announces U.S. FDA Approval of APONVIE™ (HTX-019) for Prevention of Postoperative Nausea and Vomiting

Heron wins FDA nod for post-operative agent to address nausea and vomiting

Heron Therapeutics, Inc. announced that it has received $76.499144 million in funding from Deep Track Capital, LP, Great Point Partners, LLC, Broadfin Holdings LLC

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Heron Therapeutics, Inc. announced that it expects to receive $76.499144 million in funding from Deep Track Capital, LP, Great Point Partners, LLC, Broadfin Holdings LLC and other investors

Is Heron Therapeutics (NASDAQ:HRTX) A Risky Investment?

Heron Therapeutics Q2 2022 Earnings Preview

Heron Therapeutics proposes 34% cut in workforce as part of cost reduction plan

Price target decreased to US$17.08

Heron Therapeutics, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2022

Heron Therapeutics, Inc. to Report Q1, 2022 Results on May 09, 2022

Heron Therapeutics, Inc., Annual General Meeting, May 24, 2022

Heron Therapeutics: Cash Is A Problem Again